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Abstract
Introduction: 18F-florbetaben and positron emission tomography were used to examine the relationships between
b-amyloid (Ab) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive
impairment (MCI).
Methods: Forty-five MCI participants were evaluated. A neocortical standardized uptake value ratio threshold ≥
1.45 was used to discriminate high from low Ab burden. Correlations were adjusted for age, gender and years of
education.
Results: High Ab burden was found in 53% of MCI. Regression analyses showed standardized uptake value ratio (r
= -0.51, P = 0.0015) and hippocampal volume (r = 0.60, P = 0.024) both contributing to episodic memory
impairment in independent fashion. White matter hyperintensities correlated with nonmemory cognition, and this
correlation was particularly associated with Ab burden.
Conclusion: Higher Ab deposition in MCI is associated with more severe memory impairment and is contributing
to early amnestic symptoms independent of hippocampal atrophy.
Introduction
The leading etiological hypothesis of Alzheimer’s disease
(AD) points to excessive brain b-amyloid (Ab) that
aggregates to form extracellular plaques and vascular
wall deposits [1]. With increasing prevalence and asso-
ciated cost of care and the likelihood of greater benefit
if therapies are applied early, earlier and more accurate
identification of AD has become a research priority.
Dementia is usually preceded by a transition period of
cognitive decline commonly referred to as mild cognitive
impairment (MCI). Characterized by an objective impair-
ment of memory and/or other cognitive domains, MCI is
not severe enough to significantly interfere with activities
of daily living [2]. The prevalence of MCI in people aged
65 is believed to be 10 to 20%, with over 10% who have
been classified as MCI converting to dementia per year
[3]. Histopathologic studies on brains of MCI subjects
have shown characteristic AD pathology including Ab pla-
ques and neurofibillary tangles in the majority of cases [4].
MCI has been further classified based on whether memory
has been affected (amnestic MCI) or spared (nonamnestic
MCI), and whether the cognitive deficit affected is mainly
in one cognitive domain (single-domain MCI) or more
than one domain (multidomain MCI). Hence, MCI can be
classified into four clinical subtypes: nonamnestic single-
domain, nonamnestic multiple domains, amnestic single-
domain (asMCI), and amnestic multiple domains
(amMCI). These subtypes probably differ in etiology and
outcome. Impaired episodic memory, which characterizes
asMCI and amMCI, is thought to be a prodromal condi-
tion for AD [3,4].
The new research diagnostic criteria for AD and MCI
allow for Ab imaging in the workup of individuals with
cognitive impairment [5,6]. Non-invasive Ab imaging to
confirm the presence of AD neuropathology could aid in
early differential diagnosis, identify at-risk individuals,
help predict or monitor disease progression, and poten-
tially evaluate the response to disease-specific therapy.
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11C-Pittsburgh Compound B (PiB) has been the most
widely used agent in dementia research to assess Ab bur-
den in vivo [7]. The major disadvantage of PiB is that it is
radiolabeled with carbon-11, which has a short decay
half-life (20 minutes) that limits its use to centers with an
onsite cyclotron and 11C-radiochemistry expertise.
To overcome these limitations, a number of novel
fluorine-18 Ab imaging tracers such as 18F-florbetaben
(BAY 94-9172) [8-10], 18F-florbetapir (AV45) [11,12]
and 18F-flutemetamol (GE067) [13,14] have been devel-
oped. The 110-minute radioactive decay half-life of
fluorine-18 allows centralized synthesis and regional dis-
tribution of these tracers as currently practiced world-
wide in the supply of 18F-fluorodeoxyglucose for routine
clinical positron emission tomography (PET) imaging.
18F-florbetaben (FBB; trans-4-(N-methyl-amino)-
4"(2-(2-(2-[18F] fluoro-ethoxy)ethoxy)-ethoxy)stilbene),
developed by Avid Radiopharmaceuticals (Philadelphia,
USA) and Bayer-Schering Pharma (Berlin, Germany), has
been shown to bind with high affinity to Ab in brain
homogenates and selectively labeled Ab plaques and cer-
ebral amyloid angiopathy (CAA) in AD tissue sections
[15]. After injection into Tg2576 transgenic mice, ex vivo
brain sections showed localization of FBB in regions with
Ab plaques as confirmed by thioflavin binding [16]. At
the tracer concentrations achieved during human PET
studies, FBB did not show binding to a-synuclein in
Lewy bodies or to tau lesions in postmortem cortices
from dementia with Lewy bodies, AD or frontotemporal
lobar degeneration patients [17]. In human studies, corti-
cal retention of FBB was significantly higher in AD
patients compared with age-matched controls and fron-
totemporal lobar degeneration patients, with binding
matching the reported postmortem distribution of Ab
plaques [9]. Phase II clinical studies further confirmed
these results [8]. FBB is highly correlated with 11C-PiB
(r = 0.97 with a slope of 0.71) [18], and was used to
detect the presence or absence of AD pathology in the
brain in participants with a wide spectrum of neurode-
generative diseases including a few MCI participants [10].
Phase III studies for FBB have reached completion [19].
Human postmortem studies have shown that while
soluble Ab oligomers and the density of neurofibrillary
tangles strongly correlate with neurodegeneration and
cognitive deficits, the density of Ab insoluble plaques
does not [20-24] and Αb burden as assessed by PET does
not strongly correlate with cognitive impairment in AD
patients [25,26]. The severity of tau pathology in AD
patients is closely related to neuronal loss [27], hippo-
campal atrophy [28,29] and memory impairment [30,31].
Amyloid imaging studies in MCI have shown an associa-
tion between Ab burden and memory [32], an association
that is believed to be mediated by hippocampal atrophy
[33]. Vascular pathology, as reflected in white matter
hyperintensities (WMH), has been shown to be asso-
ciated with cognitive impairment, particularly affecting
working memory and executive function, as well as
visuospatial abilities among people with MCI [34].
The purpose of this study was to characterize FBB
binding in a well-characterized MCI cohort, and to
explore the relationships of Ab burden cognitive perfor-
mance, hippocampal volume (HV), and WMH.
Materials and methods
Participants
Forty-five participants fulfilling Petersen’s criteria for MCI
[3] were recruited between June 2008 and December 2009
from memory disorder specialists. Fifteen healthy older
controls and 15 patients who met National Institute of
Neurological Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association criteria for probable
AD, which were previously described in an earlier study
[9], were used for comparison against the MCI cohort.
Consistent with the consensus criteria for MCI at the
time of enrolment [3], all participants (and their next of
kin) reported a history of cognitive decline and had
objective cognitive impairment on neuropsychological
assessment but remained generally independent in daily
activities. In addition, participants had to be at least 60
years of age, had at least 7 years of formal education,
spoke fluent English, were capable of giving informed
consent, had a reliable informant capable of giving a col-
lateral history, were able to tolerate a brain magnetic
resonance imaging (MRI) scan, did not meet the National
Institute of Neurological Disorders and Stroke-Associa-
tion Internationale pour la Recherché et l’Enseignement
en Neurosciences criteria for the diagnosis of vascular
dementia, and scored ≥ 24 on the Mini-Mental State
Examination (for detailed exclusion criteria, see Table S1
in Additional file 1). These participants were referred
from local specialist public and private memory disorders
clinics upon being diagnosed with MCI and had no other
evidence of significant neurodegenerative disease, moder-
ate or severe psychiatric illness, drug or alcohol depen-
dence, or participated in any anti-Ab therapeutic trial
prior to enrolment.
The recruitment criterion was defined as having at least
one test score falling 1.5 standard deviations below pub-
lished means. For precision, subsequent classification of
participants into MCI subtypes by Petersen’s criteria [3]
was based instead on test scores falling 1.5 standard
deviations below the mean of a carefully screened and
demographically well-matched cohort living in the same
region as the participants. This cohort consisted of 45
healthy older participants from the Australian Imaging
Biomarkers and Lifestyle flagship study of ageing [35]
with no history of cognitive decline who had negative
brain PiB scans, normal brain MRI, Clinical Dementia
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Rating = 0 and Clinical Dementia Rating sum of boxes =
0, and had no psychiatric illness.
Approval for the study was obtained from the Austin
Health Human Research Ethics Committee. Written
informed consent for participation was obtained from
all participants prior to screening. Safety monitoring
consisted of clinical observation, baseline ECG, hematol-
ogy and biochemistry testing and measurement of vital
signs before and after tracer injection. Vital signs, hema-
tology, and biochemistry testing were repeated 1 week
after injection. Participants were asked about possible
adverse events after their PET scan and 1 week after
injection.
Neuropsychological evaluation
Neuropsychology evaluation was conducted within 24.5 ±
15.5 days of the FBB PET scan by a licensed neuropsy-
chologist. Evaluation consisted of the Mini-Mental State
Examination, the Clinical Dementia Rating, the California
Verbal Learning Test Second Edition, the Rey Complex
Figure Test (RCFT), Logical Memory I and II (Wechsler
Memory Scale; Story A only), the Controlled Oral Word
Association Test, Categorical Fluency, the Boston Nam-
ing Task (30-item version), Digit Symbol-coding and
Digit Span.
Individual composite episodic memory z scores (EM)
were generated in 44 participants by averaging the z
scores for delayed recall trials of the RCFT, the California
Verbal Learning Test Second Edition, and Logical Mem-
ory II. The RCFT delayed recall score was missing for
another participant and was substituted with the RCFT
immediate delay score because the relationship between
scores on the immediate and the delayed recall trials was
very strong (r = 0.93). Composite nonmemory z scores in
all 45 participants were calculated by averaging the
z scores for the Boston Naming Task, the Controlled
Oral Word Association Test, Categorical Fluency, Digit
Span, Digit Symbol-coding and RCFT copy [32].
Image acquisition
Magnetic resonance imaging
A three-dimensional T1-weighted magnetization prepared
rapid gradient echo sequence and a fluid-attenuated inver-
sion recovery sequence were performed on either a 1.5 T
or a 3 T magnetic resonance scanner prior to the PET
scan.
18F-florbetaben imaging
Labeling was carried out in the Austin Health Centre for
PET, as previously described [9]. Mean specific activity
at the time of injection for MCI was 60 ± 29 GBq/μmol.
Imaging was performed with a three-dimensional GSO
Philips Allegro PET camera. A 2-minute transmission
scan using a rotating 137Cs source was performed for
attenuation correction immediately prior to scanning.
Each MCI participant received on average 286 ± 19
MBq FBB intravenously over 38 ± 17 seconds. Images
were reconstructed using a three-dimensional RAMLA
algorithm (Philips, Cleveland, USA). Images obtained
between 90 and 110 minutes post injection were used
for the analysis.
Image analysis
All image analysis was performed by experienced opera-
tors blind to the clinical status and cognitive test scores
of the subjects.
Extraction of HVs from the three-dimensional magne-
tization prepared rapid gradient echo MRI data in 43
MCI cases was performed using a commercial, US Food
and Drug Administration-approved, fully automated
volumetric measurement program (NeuroQuant®) [36].
Preprocessing of the fluid-attenuated inversion recovery
images was performed to correct for bias field effects and
remove noise using anisotropic diffusion prior to manual
segmentation of deep WMH. Manual segmentation of
the WMH (PR) was performed using MRIcro software
[37]. The total WMH volume in each MCI subject was
calculated, as well as the number of individual lesions.
All volumes were normalized for head size using the total
intracranial volume, defined as the sum of gray matter,
white matter and cerebrospinal fluid volumes.
Spatial normalization and co-registration of the PET
and MRI images was performed using SPM8 [38]. PET
images were processed with a semiautomatic volume of
interest method. This method used a preset template of
narrow cortical volume of interest that was either applied
to the spatially normalized MRI and then transferred to
the co-registered FBB scan or applied directly to the spa-
tially normalized FBB scan. Minor manual adjustments
were made to ensure that overlap with white matter and
cerebrospinal fluid was minimized. Mean radioactivity
values were obtained from the volume of interest for the
cortical, subcortical and cerebellar regions. The cerebellar
cortical volume of interest was placed taking care to
avoid cerebellar white matter. All volume of interest pla-
cement was performed by a single experienced operator
(VLV) blind to the clinical status of the individuals. No
correction for partial volume effects was applied to the
PET data.
The standardized uptake value, defined as the decay-
corrected brain radioactivity concentration normalized
for injected dose and body weight, was calculated for all
regions. These values were then used to derive the stan-
dardized uptake value ratio (SUVR), which was refer-
enced to the cerebellar cortex. Neocortical Ab deposition
was expressed as the average SUVR of the mean for the
following cortical regions of interest: frontal (consisting
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of dorsolateral prefrontal, ventrolateral prefrontal, and
orbitofrontal regions), superior parietal, lateral temporal,
lateral occipital, and anterior and posterior cingulate.
To identify a SUVR cutoff point, a hierarchical cluster
analysis of the neocortical SUVR of FBB scans in healthy
control participants was performed similar to that pre-
viously described [10]. The cutoff value for high neocor-
tical SUVR in this study was defined as ≥ 1.45.
Statistical analysis
Independent-sample t-tests were used to compare means
of MCI subtypes with healthy controls and AD patients,
and to compare means within the MCI subtypes. Categori-
cal differences were assessed using Fisher’s exact test.
Pearson’s or Spearman’s rank correlation analyses were
conducted to assess the degree of linear relationship
between neuroimaging variables (SUVR, HV, WMH) with
composite EM and nonmemory z scores, adjusting for age,
gender and years of education. Data are presented as
mean ± standard deviation unless otherwise stated.
Adjustment for multiple testing was not performed.
Role of the funding source
The funding sources had no role in the data analyses
and interpretation. The corresponding author had full
access to all data presented in this study and had final
responsibility for the decision to submit for publication.
Results
Population characteristics
Table 1 summarizes the demographic characteristics of
the 45 MCI participants subclassified by Petersen criteria
[3]. The table also details the demographic characteristics
of the previously reported healthy controls and AD sub-
jects for comparison [9]. Twenty-nine participants were
classified as having amMCI and 12 were assessed as having
asMCI. Two participants were classified as nonamnestic
single-domain MCI and two as nonamnestic multiple-
domain MCI. Given the low number of nonamnestic MCI
cases, they were grouped together for all analyses.
Neuroimaging results
Table 2 summarizes the neuroimaging results. Fifty-three
percent of MCI participants presented with high Ab bur-
den as measured by FBB. In the asMCI cases this preva-
lence rose to 83%, significantly higher than other
subcategories. HVs were similar between MCI subgroups
(Table 2). Figure 1 shows low and high neocortical FBB
retention in two amnestic MCI participants of the same
age, gender and Mini-Mental State Examination scores.
Figure 2 shows the boxplots of neocortical SUVR by
clinical subclassification. Only one of the four nonamnes-
tic MCI cases showed high neocortical FBB retention.
Ten (83%) asMCI cases had high retention compared
with 13 (45%) amMCI cases (Fisher’s exact test, P =
0.038).
Table 3 shows the characteristics and neuroimaging
data in the different MCI subtypes when split into low
(SUVR < 1.45) and high (SUVR ≥ 1.45) Ab groups. MCI
participants with high cortical FBB retention performed
more poorly on cognitive tasks involving memory. The
Clinical Dementia Rating scores were slightly but signifi-
cantly higher in those with high Ab deposition. There
were no significant differences in HV and WMH
between high and low SUVR groups.
Correlation analysis
There was a strong relationship between neocortical
SUVR and EM in MCI (r = -0.51, P = 0.0015) (Figure 3).
After accounting for HV, the correlation persisted (r =
-0.49, P = 0.015).
There was also a relationship between HV and EM in
the entire MCI cohort (r = 0.60, P = 0.024). Accounting
for neocortical SUVR, the correlation between HV and
EM also remained significant (r = 0.33, P = 0.042) for
the entire MCI cohort.
Table 1 Demographics
MCI subtype
HC (n = 15) AD (n = 15) All MCI (n = 45) naMCI (n = 4) asMCI (n = 12) amMCI (n = 29)
Age 68.8 ± 6.5 69.5 ± 9.7 72.7 ± 6.5 74.5 ± 6.8 70.2 ± 6.9 73.5 ± 6.3
Years of education 13.3 ± 3.6 12.8 ± 3.9 13.6 ± 3.6 14.8 ± 1.7 15.2 ± 3.9 12.8 ± 3.6
Males, n (%) 8 (53) 10 (66.7) 29 (64) 4 (100) 7 (58) 18 (62)
MMSE 29.5 ± 0.8 23.7 ± 3.8 27.2 ± 1.8AB 27.3 ± 1.3AB 27.4 ± 2.2AB 27.2 ± 1.7AB
CDR 0.0 ± 0.0 1.0 ± 0.0 0.4 ± 0.2AB 0.4 ± 0.3AB 0.5 ± 0.1AB 0.4 ± 0.2AB
CDR SOB 0.0 ± 0.0 4.8 ± 1.1 1.5 ± 1.0AB 1.8 ± 1.0AB 1.5 ± 1.1AB 1.5 ± 0.9AB
Composite EM 0.0 ± 0.8 -3.5 ± 0.8 -2.1 ± 1.1AB -0.6 ± 0.4ABC -2.3 ± 1.1AB -2.2 ± 1.1AB
Composite NM 0.6 ± 1.1 -3.1 ± 1.8 -0.9 ± 0.9AB -0.8 ± 1.0AB -0.1 ± 0.4ABD -1.3 ± 0.8AB
AD, Alzheimer’s disease; amMCI, amnestic multidomain mild cognitive impairment; asMCI, amnestic single-domain mild cognitive impairment; CDR, Clinical
Dementia Rating; EM, episodic memory z score; HC, healthy older controls; MCI, mild cognitive impairment; naMCI, nonamnestic mild cognitive impairment; NM,
nonmemory z score; SOB, sum of boxes. AP < 0.05, MCI subtype compared with HC. BP < 0.05, MCI subtype compared with AD. CP < 0.05, naMCI compared with
asMCI and amMCI. DP < 0.05, asMCI compared with naMCI and amMCI.
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There was a relationship between WMH volume and
nonmemory z scores (r = -0.60, P = 0.03; Spearman’s r =
-0.48, P = 0.0008). This correlation was amplified in the
high SUVR subgroup (r = -0.71, P = 0.014; Spearman’s r =
-0.57, P = 0.0035), but was not present in the low SUVR
subgroup (see Figure S1 in Additional file 2). No correla-
tion was found between WMH and neocortical SUVR, HV
or EM.
Discussion
Ab burden and memory impairment
This study provides support for the use of FBB PET to
assess brain Ab plaque levels in individuals with MCI.
FBB presents with similar characteristics to PiB, includ-
ing short scan acquisition time and a good safety and tol-
erability profile. The longer radioactive half-life of
Table 2 Neuroimaging
MCI subtype
HC (n = 15) AD (n = 15) All MCI (n = 45) naMCI (n = 4) asMCI (n = 12) amMCI (n = 29)
Neocortical SUVR 1.26 ± 0.22 1.96 ± 0.27 1.54 ± 0.27AB 1.50 ± 0.35B 1.66 ± 0.20AB 1.49 ± 0.28B
High b-amyloid, n (%) 3 (20) 15 (100) 24 (53)B 1 (25)B 10 (83)AC 13 (45)B
Hippocampal volume (cm3) 7.1 ± 0.9 7.1 ± 0.8 7.0 ± 0.8 7.2 ± 1.0
WMH volume (cm3) 10.2 ± 11.0 13.3 ± 15.5 4.8 ± 6.6C 12.0 ± 11.4
AD, Alzheimer’s disease; amMCI, amnestic multidomain mild cognitive impairment; asMCI, amnestic single-domain mild cognitive impairment; HC, healthy older
controls; MCI, mild cognitive impairment; naMCI, nonamnestic mild cognitive impairment; SUVR, standard uptake value ratio; WMH, white matter hyperintensities.
AP < 0.05, MCI subtype compared with HC. BP < 0.05, MCI subtype compared with AD. CP < 0.05, asMCI compared with amMCI.
Figure 1 Sagittal and transaxial 18F-florbetaben positron emission tomography images of two mild cognitive impairment participants.
Representative sagittal and transaxial 18F-florbetaben positron emission tomography (PET) images of two female mild cognitive impairment participants,
both of the same age (73 years old) and with the same Mini-Mental State Examination score of 27. While the PET images on the left show nonspecific
retention in white matter, the PET images on the right show high cortical 18F-florbetaben retention in the typical pattern seen in Alzheimer’s disease,
with highest retention in the precuneus/posterior cingulate, frontal and lateral temporal cortices. SUVR, standard uptake value ratio.
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fluorine-18 makes FBB PET a promising clinical tool for
the detection of AD pathology in vivo.
The observation that 53% of scans had high FBB reten-
tion is consistent with the prevalence of AD neuropathol-
ogy at postmortem in those with MCI or in those who
progress from MCI to dementia [39,40] and with reports
that have used PiB PET or cerebrospinal fluid measures
to assess brain Ab in MCI [41-43]. There was a strong
correlation between FBB retention and episodic memory
impairment, the cognitive domain that is the best predic-
tor of AD [44]. In contrast to several Ab imaging studies
using PiB [33,45], we found the correlation to be inde-
pendent of HV - suggesting that Ab might have a direct
effect on memory storage and retrieval. This is supported
by functional MRI studies of the default network that
have shown a relationship between regional Ab tracer
retention and disrupted synaptic activity well beyond the
hippocampus in neuronal memory circuits [46].
Despite the multifaceted nature of memory and other
cognitive domains affected by a wide spectrum of physical
and environmental factors, the arbitrary distinction of sin-
gle-domain amnestic MCI from multidomain amnestic
MCI appears to increase confidence of in vivo AD pathol-
ogy. In our cohort, approximately 80% of asMCI presented
with high FBB retention. The Alzheimer’s Disease Neuroi-
maging Initiative (ADNI) Grand Opportunities criterion
for late MCI, which relies on a single test score of logical
memory [47], also has value for increasing confidence of
in vivo Ab neuropathology [48]. Indeed 24 participants in
our cohort could be reclassified as late MCI, and 19 of
these (79%) had positive scans. On the contrary, the criter-
ion for early MCI [47] may have value in raising the possi-
bility of neuropathology other than Ab. In our cohort,
eight participants could be reclassified as early MCI using
the ADNI Grand Opportunities criteria, and five of these
(63%) had negative scans. It would be of interest to know
the prognostic value of conversion to AD and non-AD
dementia in the different classifications of MCI in our
cohort, and longitudinal follow-up of this cohort is
ongoing.
The z scores were calculated from a demographically
matched cohort of participants with normal cognitive
scores, normal brain MRI scans and negative PiB scans.
Our study therefore included some subjects who did not
score 1.5 standard deviations below published means on
any of the episodic memory tests, and some subjects who
performed poorly on word list recall or complex figure
recall but not on the Logical Memory task. Consequently,
Figure 2 Boxplots of b-amyloid burden by clinical classification [3]. b-amyloid (Ab) burden in the Alzheimer’s disease (AD) group was
significantly higher (+) compared with the mild cognitive impairment (MCI) and healthy control (HC) groups. Ab burden was high in 83% of the
amnestic single-domain MCI (asMCI) participants and significantly higher than in HC (†). Only one nonamnestic MCI (naMCI) subject presented
with high 18F-florbetaben retention. Dotted line, threshold between high and low Ab burden. amMCI, amnestic multidomain MCI; SUVR,
standard uptake value ratio.
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13 (29%) participants did not meet ADNI Grand Oppor-
tunities criteria for either early or late MCI. This broader
definition of MCI may lead to different results. The
inclusion of MCI subjects with such a wide range of
memory test scores may have allowed a better assessment
of the correlation of episodic memory impairment with
brain Ab burden. Significant correlation between Ab
deposition and memory has been reported previously
[26,32,33], but has not been consistently found in other
studies [43,45]. In contrast to episodic memory, and
Table 3 Demographic, cognitive and neuroimaging data in the high and low 18F-florbetaben retention groups
All MCI (n = 45)
Low Ab (SUVR < 1.45) High Ab (SUVR ≥ 1.45)
Number (% of total) 21 (47) 24 (53)
Age 71.8 ± 6.1 73.5 ± 6.9
Years of education 13.5 ± 3.0 13.8 ± 4.2
MMSE 27.9 ± 1.4 26.7 ± 1.9*
CDR 0.4 ± 0.2 0.5 ± 0.0*
CDR SOB 1.3 ± 0.9 1.6 ± 1.0
Composite EM -1.4 ± 0.8 -2.8 ± 1.0*
Composite NM -1.0 ± 0.9 -0.8 ± 0.8
Neocortical SUVR 1.30 ± 0.09 1.75 ± 0.19*
Hippocampal volume (cm3) 7.4 ± 1.1 6.9 ± 0.8
WMH volume (cm3) 9.9 ± 10.2 10.5 ± 11.8
Ab, b-amyloid; CDR, Clinical Dementia Rating; EM, episodic memory z score; MCI, mild cognitive impairment; NM, nonmemory z score; SOB, sum of boxes, SUVR,
standard uptake value ratio; WMH, white matter hyperintensities. *P < 0.05.
Figure 3 Relationship between b-amyloid burden and episodic memory in mild cognitive impairment. There was a significant correlation
between b-amyloid (Ab) burden and memory impairment, which was independent of hippocampal volume. Dotted line, threshold between
high and low Ab burden. amMCI, amnestic multidomain mild cognitive impairment; asMCI, amnestic single-domain mild cognitive impairment;
naMCI, nonamnestic mild cognitive impairment; SUVR, standard uptake value ratio.
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consistent with previous reports from PiB studies, no
association was observed between neocortical FBB reten-
tion and composite nonmemory scores [32], supporting
the notion that nonmemory domains at the MCI stage
are not directly susceptible to Ab deposition and are
more strongly influenced by other neurodegenerative
conditions within the MCI cohort.
PiB studies have shown that Ab deposition is an early
event in the development of AD, preceding the clinical
phenotype by several years [49]. Furthermore, the accumu-
lation of Ab is a slow process that tends towards a plateau
as dementia progresses [26,50]. The mean neocortical
SUVR in the high FBB MCI was 50% higher than in
healthy controls with low FBB (1.75 ± 0.19 vs. 1.17 ± 0.11,
respectively), and 12% lower than in AD patients (1.75 ±
0.19 vs. 1.96 ± 0.27, respectively). Consequently it can be
predicted that Ab burden in the MCI subjects with high
FBB will reach the Ab burden typical of AD within 5 to
7 years [26,51].
Hippocampal atrophy
Current hypotheses suggest that memory decline is pre-
ceded by hippocampal atrophy, which in turn is preceded
by Ab deposition [33,50]. While Ab deposition is a hall-
mark of AD pathology, hippocampal atrophy is a com-
mon feature of AD that correlates well with episodic
memory dysfunction and has emerged as a biomarker for
this condition. However, hippocampal atrophy is not spe-
cific for AD and may be found in frontotemporal lobar
degeneration, dementia with Lewy bodies and vascular
dementia.
In our MCI cohort, accounting for HV had a slight
effect on the strong correlation between Ab burden and
EM. After accounting for neocortical SUVR, the correla-
tion between HV and EM was still present but less signif-
icant. These results suggest a direct effect of Ab on
memory networks, and are somewhat at odds with the
hypothesis that hippocampal atrophy mediates Ab effects
on EM [33]. This discrepancy may be explained by the
different approaches in the recruitment of MCI cohorts.
White matter hyperintensities
Recent work in healthy older and vascular dementia indi-
viduals suggested that Ab deposition and WMH volumes
have independent etiologies and independent impacts on
cognition [52,53]. While Ab deposition is associated with
altered activity patterns in the default network during
memory encoding tasks [46], WMH are associated with a
faster decline in global cognitive performance, executive
function and processing speed in MCI subjects [54]. This
observation is consistent with our finding that the major-
ity (83%) of asMCI in this study had high Ab deposition
and a relatively low WMH volume, where amMCI cases
who presented with a more variable FBB retention had
significantly higher WMH volumes instead. The higher
WMH volumes in the amMCI subtype compared with
the asMCI subtype also suggest that cognition in the
amMCI subtype is less specifically affected by Ab deposi-
tion compared with the asMCI subtype for it may also be
affected by other underlying conditions associated with
high WMH volumes [54]. In our MCI cohort there was
no direct correlation between WMH volume and Ab bur-
den. An association between WMH volume and compo-
site scores did present in nonmemory-related tasks but
only in the high Ab burden subjects. This observation
supports the notion that there may be a synergistic inter-
action between Ab deposition and WMH on nonmem-
ory-related cognitive functions [55], even though no
direct relationship between Ab deposition and nonmem-
ory-related cognitive functions was found.
Clinical utility of 18F-florbetaben PET in MCI
Each of the four MCI subtypes has been proposed to be
associated with an increased risk of developing a particular
type of dementia [3]. One study showed that while most
amnestic MCI progressed to AD, nonamnestic MCI was
more likely to progress to other types of dementia [56]. In
the current study, 21 (47%) MCI cases had low Ab burden.
Our findings suggest that the cognitive impairment in
these MCI participants might not be related to Ab deposi-
tion, and other factors such as depression [57], cerebrovas-
cular disease [54], or non-AD pathologies [10,25] should
be considered. A significant proportion of individuals with
MCI do not progress to dementia or return to normal
[56]. These individuals will probably be in our group with
low FBB retention as shown in longitudinal PiB imaging
studies of MCI, but longitudinal follow-up of our cohort is
required to confirm this hypothesis. In addition to Ab
deposition, environmental factors, brain and/or cognitive
reserve and the presence of other age-related diseases may
influence and modulate the development and progression
of cognitive impairment. To ascertain the clinical utility of
Ab imaging will require follow-up of participants in longi-
tudinal studies. Such studies are underway, including the
ADNI and Australian Imaging Biomarkers and Lifestyle
(AIBL) trial. Longitudinal follow-up of the present cohort
is also in progress.
Limitations
Limitations of the present study include the relatively
small numbers and the single-center setting. Findings
from this study warrant validation in a larger multicenter
cohort. Moreover, given the wide day-to-day variance of
cognitive test scores, longitudinal studies will be needed
to further corroborate our initial findings with regards to
the association between cognition and neuropathology.
Another limitation that might hinder comparison with
similar studies is the highly characterized normal cohort
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used to generate the z scores that, with a smaller var-
iance, results in more stringent cutoff values. Our cohort
may therefore include participants with minor deficits
who would be otherwise classified as normal when pub-
lished norms standards are applied. On the contrary, all
subjects in the study were referred from memory disor-
der specialists with a clinical diagnosis of MCI, so they
represent the patient population likely to be investigated
with Ab imaging. Another limitation of the study is that
the brain volumetric assessments pool data obtained on
MRI scanners with different field strengths. Given its
relevance in memory performance, this study focused on
the regional atrophy of the hippocampus, but cortical
atrophy in other regions of the brain - such as the poster-
ior cingulate gyrus or the parietal or frontal lobes - might
possibly explain some additional variance in memory
impairment, thus affecting the observed relationship with
Ab. Further studies assessing regional brain atrophy and
its relation to cognition and Ab are needed to help eluci-
date the potential interplay between these different
factors.
Conclusion
Higher Ab deposition in MCI as measured by FBB is
associated with more severe memory impairment and is
independently correlated with episodic memory impair-
ment after adjusting for hippocampal volume. Moreover,
the use of FBB may prove useful in the early differential
diagnosis of MCI, identifying subjects with and without
brain Ab, potentially aiding early therapeutic interven-
tions as well as helping to predict prognosis.
Additional material
Additional file 1: Table S1 presenting exclusion criteria.
Additional file 2: Figure S1 showing the relationship between WMH
and nonmemory scores in MCI subjects with low and high Ab. There
was a significant correlation between WMH and nonmemory scores in
MCI subjects with high Ab in the brain, but the association was not
present in the low Ab subgroup. naMCI, nonamnestic mild cognitive
impairment.
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